Reviva Pharmaceuticals Revenue
Biotechnology Research • 
Cupertino, California, United States • 11-20 Employees
Reviva Pharmaceuticals revenue & valuation
| Annual revenue | $1,711,100 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $5,500,000 |
| Total funding | $57,000,000 |
Key Contacts at Reviva Pharmaceuticals
Richard Margolin
Member, Board Of Directors
Christine Li
Global Strategic Planning And Finance Director
Company overview
| Headquarters | 10080 N Wolfe Rd, Suite SW3-200, Cupertino, California 95014, US |
| Phone number | +14085018881 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Employees | 11-20 |
| Socials |
Reviva Pharmaceuticals Email Formats
Reviva Pharmaceuticals uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@revivapharma.com), used 80% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@revivapharma.com | 80% |
{first name}{last name} | johndoe@revivapharma.com | 20% |
About Reviva Pharmaceuticals
NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market. Speed without sacrificing quality is one of the hallmarks of Reviva’s product development model. The company has a strong patent portfolio and promising multiple products in the pipeline at various stages of development. The company’s lead product RP5063 is a multimodal neuromodulator which has successfully completed the global Phase 2 clinical trials and has shown a superior efficacy and safety profile for schizophrenia and schizo affective disorder. After having a very successful End of Phase 2 ( EOP2 ) meeting with U.S. FDA, the company is now preparing to start the global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The company is also planning to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Reviva Pharmaceuticals has 5 employees across 5 departments.
Departments
Number of employees
Funding Data
Explore Reviva Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.
Reviva Pharmaceuticals Tech Stack
Discover the technologies and tools that power Reviva Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.
Video players
Security
Security
JavaScript libraries
CDN
JavaScript libraries
Miscellaneous
Programming languages
Blogs
Page builders
Analytics
Switzerland
United Kingdom
Czechia
Germany
Canada
Frequently asked questions
4.8
40,000 users
